Development of cell-mediated immunity to Marek's disease tumor cells in chickens inoculated with Marek's disease vaccines

J Natl Cancer Inst. 1978 Nov;61(5):1273-80. doi: 10.1093/jnci/61.5.1273.

Abstract

Chickens inoculated with herpesvirus of turkeys or with apathogenic or attenuated vaccine strains of Marek's disease virus (MDV) developed a T-cell-mediated immune response to Marek's disease (MD) tumor cells. This immune response was detected in a 4-hour 51Cr-release assay in which effector cells obtained from spleens of vaccinated chickens were reacted with 51Cr-labeled target cells of an MD lymphoblastoid cell line (MSB-1). The cytotoxic effector cells generated by the vaccine viruses had characteristics similar to those noted previously for anti-MSB-1 effector cells generated by MDV. The immune response was specific to MSB-1 cells, because another target cell line (TLT) antigenically unrelated to MSB-1 cells was not lysed by the effector cells nor did the unrelated target cells inhibit the cytotoxicity of effector cells against MSB-1 target in a cold-target inhibition assay. Because MSB-1 cells contain MD tumor-associated surface antigen, we postulated that the immune response detected in the vaccinated chickens may be directed against this antigen and that the antitumor antigen immunity may play a role in the mechanism of vaccine protection against lymphoma development by pathogenic MDV.

MeSH terms

  • Animals
  • Antigens, Neoplasm / administration & dosage*
  • Antigens, Surface
  • Antigens, Viral / administration & dosage*
  • Chickens
  • Cytotoxicity, Immunologic
  • Herpesvirus 2, Gallid / immunology*
  • Hot Temperature
  • Immunity, Cellular*
  • In Vitro Techniques
  • Marek Disease / immunology*
  • Neuraminidase / pharmacology
  • T-Lymphocytes / immunology
  • Viral Vaccines / pharmacology*

Substances

  • Antigens, Neoplasm
  • Antigens, Surface
  • Antigens, Viral
  • Viral Vaccines
  • Neuraminidase